Pharmaceuticals News and Research

RSS

China Nepstar Chain Drugstore second-quarter revenue increases 5.8% to RMB565 million

China Nepstar Chain Drugstore Ltd., the largest retail drugstore chain in China based on the number of directly operated stores, today announced its unaudited financial results for the quarter ended June 30, 2010.

11 Aug 2010

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Intellect Neurosciences, Inc a biopharmaceutical company with an internal preclinical and clinical-stage pipeline and licenses with major pharmaceutical companies covering products in late-stage clinical trials, announced that it has received a Notice of Allowance from the United States Patent and Trademark Office related to RV01 and RV02, the Company's two lead vaccine candidates. The Notice of Allowance is a written communication stating that the patent application has been allowed and will be granted as a new patent. RV01 and RV02, generated using the Company's RECALL-VAX technology, have the potential to delay the onset of or prevent Alzheimer's disease in individuals susceptible by age, genetic or other risk factor.

11 Aug 2010

Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

Trigemina, Inc., a Mountain View, CA based pharmaceutical company, reports positive results from its Phase IIa proof-of-concept clinical trial for TI-001 in Chronic Daily Headache. The trial is a collaborative effort between Trigemina and Dr. Egilius Spierings of MedVadis Research Corporation located outside of Boston, and compares intranasal TI-001 with placebo in patients suffering from CDH.

11 Aug 2010

StemCells second-quarter net loss decreases to $4.61 million

StemCells, Inc., a leading stem cell company developing and commercializing novel stem cell therapeutics and tools for use in stem cell-based research and drug discovery, today reported financial results and business highlights for the second quarter ended June 30, 2010.

11 Aug 2010

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, announced today that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of its novel once-daily oral antibiotic Restanza to treat community acquired bacterial pneumonia (CABP). The trial is the first prospectively designed superiority study to be conducted in CABP.

11 Aug 2010

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule drugs to treat cancer, today announced it has completed a $32 million Series C financing with new investor Clarus Ventures leading the round.

11 Aug 2010

Clarient receives patent for Mammostrat breast cancer prognostic test

Clarient, Inc. a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United States Patent and Trademark Office and the European Patent Office have allowed patents covering the technology behind Clarient Insight Dx Mammostrat, a test designed to aid in the classification of the risk of recurrence of breast cancer following surgery and initial treatment.

11 Aug 2010

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

Advanced Cell Diagnostics, Inc., announces the launch and immediate availability of RNAscope™ FFPE Assay Kit, a line of RUO products designed to detect RNA biomarkers in routine Formalin-Fixed, Paraffin-Embedded tissue specimens with single molecule sensitivity.

From Advanced Cell Diagnostics 11 Aug 2010

Omeros net loss for second-quarter 2010 increases to $7.8 million

Omeros Corporation, a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced financial results for the three and six months ended June 30, 2010.

11 Aug 2010

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Noven Pharmaceuticals, Inc. today announced that it has entered into a Product and Trademark Acquisition Agreement with affiliates of Shire plc pursuant to which Noven will acquire global rights to Daytrana® (methylphenidate transdermal system) from Shire.

11 Aug 2010

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Research at the Babraham Institute, investigating how white blood cells known as B cells develop, has revealed that genes from the Phosphatidylinositol 3-kinase family of enzymes are critical in enabling the B cells to produce antibodies in the spleen and lymph nodes.

10 Aug 2010

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Vertex Pharmaceuticals Incorporated today announced results from the Phase 3 ILLUMINATE study, which was designed to evaluate whether there was any benefit to extending therapy from 24 to 48 weeks in people whose hepatitis C virus (HCV) was undetectable at weeks 4 and 12 of treatment (extended rapid viral response or eRVR).

10 Aug 2010

Sharps Compliance reports revenue of $4.2M for fourth-quarter fiscal 2010

Sharps Compliance Corp., a leading full-service provider of cost-effective management solutions for medical waste and unused dispensed medications generated outside the hospital and large healthcare facility setting, today reported financial results for the fourth quarter and fiscal year ended June 30, 2010.

10 Aug 2010

China Sky One second-quarter 2010 total revenues up 26.7%

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced record financial results for the second quarter of 2010.

10 Aug 2010

China Pharma second-quarter revenue increases 22% to $16.6 million

China Pharma Holdings, Inc., a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Teva completes ratiopharm acquisition

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of ratiopharm, Germany's second largest generics producer. Following the acquisition, Teva will be the number one generic company in Europe, holding the leading market position in ten countries, as well as ranking in the top three in seven additional countries. In addition, the transaction will significantly increase Teva's sales in Canada.

10 Aug 2010

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reports a financial update as of June 30, 2010. In addition, the Company provides a progress update of its MARINE and ANCHOR trials, the two on-going Phase 3 clinical trials of its lead product candidate AMR101 for treating elevated triglyceride levels.

10 Aug 2010

Penwest Pharmaceuticals signs merger agreement with Endo Pharmaceuticals

Penwest Pharmaceuticals Co. today announced that it has entered into a merger agreement under which its long-time partner in the development and commercialization of Opana ER, Endo Pharmaceuticals, has agreed to acquire all of the common stock of Penwest for $5.00 per share in cash. The total equity value of the transaction is approximately $168 million.

10 Aug 2010

Scientists identify compound to inhibit wild-type HIV-1 protease

Drug resistance remains a major problem in combating HIV infection, but a different approach to drug development could be the answer.Current viral inhibitors target the HIV-1 protease function with a competitive mechanism. Writing in the BJ ChemBio Knowledge Environment of the Biochemical Journal, Max Chang and colleagues from the Scripps Research Institute, La Jolla, suggest that pharmaceutical companies look at compounds that use an allosteric non-competitive mechanism of inhibition.

10 Aug 2010

Weifang Shengtai to supply Kelun with 10,000 tons of dextrose monohydrate injection grade

Shengtai Pharmaceutical, Inc. announced on August 6, 2010 that Weifang Shengtai Pharmaceutical Co., Ltd ("Weifang Shengtai"), its operating subsidiary in China, entered into an agreement with Kelun Pharmaceutical ("Kelun") to supply Kelun with 10 thousand tons of dextrose monohydrate injection grade: Kelun Guizhou will be supplied with 7 hundred tons and Kelun Sichuan with 9.3 thousand tons. The agreement is entered into at reasonable prices and will be carried out by prepayments.

10 Aug 2010

Pharmaceuticals News and Research

China Nepstar Chain Drugstore second-quarter revenue increases 5.8% to RMB565 million

Intellect Neurosciences receives patent for Alzheimer's disease vaccine

Trigemina reports positive results from TI-001 Phase IIa clinical trial for Chronic Daily Headache

StemCells second-quarter net loss decreases to $4.61 million

Advanced Life Sciences reaches SPA agreement with FDA for Restanza Phase 3 study

TetraLogic raises $32 million in Series C financing to advance clinical development of TL32711 cancer drug

Clarient receives patent for Mammostrat breast cancer prognostic test

ACD launches RNAscope Formalin-Fixed, Paraffin-Embedded Assay Kit

Omeros net loss for second-quarter 2010 increases to $7.8 million

Noven enters agreement to acquire global rights to ADHD drug Daytrana from Shire

Study results provide rationale for use of PI3K inhibitors in therapeutic settings

Vertex reports results from Phase 3 ILLUMINATE study of telaprevir-based therapy for hepatitis C

Sharps Compliance reports revenue of $4.2M for fourth-quarter fiscal 2010

China Sky One second-quarter 2010 total revenues up 26.7%

China Pharma second-quarter revenue increases 22% to $16.6 million

Teva completes ratiopharm acquisition

Amarin provides progress update on MARINE and ANCHOR trials for treating elevated triglyceride levels

Penwest Pharmaceuticals signs merger agreement with Endo Pharmaceuticals

Scientists identify compound to inhibit wild-type HIV-1 protease

Weifang Shengtai to supply Kelun with 10,000 tons of dextrose monohydrate injection grade

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence